Dovitinib lactate: Phase II data

Data from 59 patients in the Phase II portion of an open-label, international Phase I/II trial showed that once-daily 500 mg oral dovitinib produced 2 partial responses, 29 cases of stable disease for >=2 months and 16 cases of stable disease for >=4 months. Median PFS and OS were 5.5 and 11.8 months, respectively. Dovitinib was well tolerated with asthenia, fatigue, hypertriglyceridemia, diarrhea and hypertension reported as the most common grade 3/4 adverse events. ...